Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1671613 | 0.85 | SMN1; SMN2 (0.50) | KMT2ARAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL12236675 | 0.85 | SMN1; SMN2 (0.50) | KMT2ARAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL1671615 | 0.85 | SMN1; SMN2 (0.50) | KMT2ARAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL944679 | 0.83 | ERN1 (0.40) | KDM4EKMT2ARAB9AALDH1A1TSHR | |
| SCHEMBL18502965 | 0.75 | KDM4E (0.44) | KDM4EKMT2AL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL18508561 | 0.75 | KDM4E (0.44) | KDM4EKMT2AL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL8488636 | 0.74 | ABL1 (0.45) | KDM4EKMT2AL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL1495245 | 0.74 | CA12 (0.50) | KDM4EKMT2AALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL18329477 | 0.74 | PTGS2 (0.42) | KDM4ERAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL944683 | 0.73 | MEN1 (0.36) | KDM4EKMT2ASMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057133-B1 | DI-AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8163742-B2 | Di-amino-substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-7872128-B2 | Benzisoxazole and isoxazolo-pyridine compounds and method of use | AMGEN INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872128-B2 | Benzisoxazole and isoxazolo-pyridine compounds and method of use | AMGEN INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2069020-B1 | BENZO[D]ISOXAZOLE DERIVATIVES AS C-KIT TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH THE OVER PRODUCTION OF HISTAMINE | AMGEN INC (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2069020-A2 | BENZO[D]ISOXAZOLE DERIVATIVES AS C-KIT TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH THE OVER PRODUCTION OF HISTAMINE | Amgen Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2057133-A2 | DI-AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080318946-A1 | Di-amino-substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080227779-A1 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227779-A1 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2008011080-A2 | BENZO(D) ISOXAZOLE DERIVATIVES AS C-KIT TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH THE OVER PRODUCTION OF HISTAMINE | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011110-A2 | DI-AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227779-A1 | Heterocyclic compounds and methods of use | KIT, TPSG1, CMA1 | KDM4E 149/4885KMT2A 749/4885L3MBTL1 4555/4885 |
| US-20080318946-A1 | Di-amino-substituted heterocyclic compounds and methods of use | KIT, CMA1, TPSG1 | KDM4E 285/4885KMT2A 647/4885L3MBTL1 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.